Amal Ghanem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amal Ghanem has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Homam Sharshira
Department of Hematology, Medical Research Institute, University of Alexandria, 47 (A) Memphis - Camp Chezar, Alexandria, Egypt
1 shared publication - Irene Lewis Mikhael
Department of Hematology, Medical Research Institute, Alexandria University, Alexandria, Egypt
1 shared publication - Maha Mohamed Adel Elgammal
Department of Hematology, Medical Research Institute, Faculty of Medicine, University of Alexandria, Alexandria, Egypt
1 shared publication - Waiel Al-Kahiry
Department of Hematology, Faculty of Medicine and Health Sciences, University of Aden, Aden, Yemen
1 shared publication
Latest Publications
- 16 November 2016
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 33 (3) , 321-326
Evaluation of Prognostic Impact of Soluble CD14 in B-Chronic Lymphocytic Leukemia
SCD14 is an acute phase reactant; few studies reported its prognostic value in B-CLL patients. This gave us the impetus to conduct this study. This study enrolled 40 newly diagnosed B-CLL Egyptian patients, presented to the Hematology Department of the Medical Research Institute in Alexandria University. The ZAP-70 was determined by flow cytometry whereas serum sCD14 concentration by human sCD14 sandwich ELISA method. The mean serum level of sCD14 was significantly higher among patients with positive ZAP-70, Binet stage C, Rai stage III–IV and high risk CLL prognostic index. It showed a significant positive correlation to the percentage of ZAP-70 expression and significant negative correlation to the hemoglobin concentration. Serum sCD14 concentration could be used to assess B-CLL patients initially as an additional prognostic marker, especially in low resources areas where flow cytometry is not available.
- 16 November 2016
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 33 (3) , 321-326
Evaluation of Prognostic Impact of Soluble CD14 in B-Chronic Lymphocytic Leukemia
SCD14 is an acute phase reactant; few studies reported its prognostic value in B-CLL patients. This gave us the impetus to conduct this study. This study enrolled 40 newly diagnosed B-CLL Egyptian patients, presented to the Hematology Department of the Medical Research Institute in Alexandria University. The ZAP-70 was determined by flow cytometry whereas serum sCD14 concentration by human sCD14 sandwich ELISA method. The mean serum level of sCD14 was significantly higher among patients with positive ZAP-70, Binet stage C, Rai stage III–IV and high risk CLL prognostic index. It showed a significant positive correlation to the percentage of ZAP-70 expression and significant negative correlation to the hemoglobin concentration. Serum sCD14 concentration could be used to assess B-CLL patients initially as an additional prognostic marker, especially in low resources areas where flow cytometry is not available.